Limited association between HRR gene alterations and HRD in molecular tumor board cancer samples: Who should be tested for HRD?

doi:10.1002/ijc.35457

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Limited association between HRR gene alterations and HRD in molecular tumor board cancer samples: Who should be tested for HRD?

International journal of cancer - 1 Sept 2025

Schubart Christoph, Tögel Lars, Carta Maria Giulia, Hetzner Philip, Helbig Lina, Zaglas Charlotte, Ziegler Maria, Stöhr Robert, Hölsken Annett, Hoyer Juliane, Ferrazzi Fulvia, Neufert Clemens, Lettmaier Sebastian, Pavel Marianne, Golcher Henriette, Mueller Sarina K, Fuchs Florian, Schulmeyer Carla E, Beckmann Matthias W, Wullich Bernd, Agaimy Abbas, Reis Andre, Hartmann Arndt, Meidenbauer Norbert, Spoerl Silvia, Haller Florian, Moskalev Evgeny A

Abstract excerpt

Alterations in Homologous Recombination Repair (HRR) Pathway genes have been found to be associated with HR-Deficiency (HRD), which is an approved biomarker for PARP Inhibitor (PARPi) treatment. The aim of a Molecular Tumor Board (MTB) is to identify molecular alterations in cancer patients with advanced tumors that may suggest off-label treatment options. So far, few studies have analyzed the presence of HRR...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Biomarkers, Tumor

Share to BRCA1 Protein

Share to BRCA2 Protein

Share to Genomic Instability

Share to Neoplasms

Share to Poly(ADP-ribose) Polymerase Inhibitors

Share to Recombinational DNA Repair

Source

Open in PubMed Open full text

Identifiers

PMID: 40278800
DOI: 10.1002/ijc.35457
PMCID: PMC12232594

Genes

BRCA1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Limited association between HRR gene alterations and HRD in molecular tumor board cancer samples: Who should be tested for HRD?PMID 40278800Read ↗

Toward More Comprehensive Homologous Recombination Deficiency Assays in Ovarian Cancer Part 2: Medical PerspectivesSemantic proximity Read ↗

Homologous recombination deficiency in diverse cancer types and its correlation with platinum chemotherapy efficiency in ovarian cancerSemantic proximity Read ↗

Prediction of homologous recombination deficiency identifies colorectal tumors sensitive to PARP inhibitionSemantic proximity Read ↗

Pan-cancer analysis of genomic scar patterns caused by homologous repair deficiency (HRD)Semantic proximity Read ↗

The Homologous Recombination Deficiency Scar in Advanced Cancer: Agnostic Targeting of Damaged DNA RepairSemantic proximity Read ↗

A novel targeted NGS panel identifies numerous homologous recombination deficiency (HRD)-associated gene mutations in addition to known BRCA mutations.Semantic proximity Read ↗

How BRCA and homologous recombination deficiency change therapeutic strategies in ovarian cancer: a review of literatureSemantic proximity Read ↗

Potential agnostic role of BRCA alterations in patients with several solid tumors: One for all, all for one?Semantic proximity Read ↗

HRDetect in Ovarian Carcinoma: Stratification and Therapeutic ImplicationsSemantic proximity Read ↗

Homologous Recombination Deficiency Testing for BRCA-Like Tumors: The Road to Clinical ValidationSemantic proximity Read ↗

Homologous Recombination Deficiency in Ovarian and Breast Cancers: Biomarkers, Diagnosis and TreatmentSemantic proximity Read ↗

Beyond HRD Status: Unraveling Genetic Variants Impacting PARP Inhibitor Sensitivity in Advanced Ovarian Cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.